Dr. Richard K. Olney, a leading physician and pioneer in clinical research on ALS, died of the disease on Jan. 27 at his home in Corte Madera, Calif. He was 64. His ... read more
Findings suggest energy deficits may contribute to neurodegenerative disorders Washington, DC — Turning off a protein that helps cells balance energy ... read more
CK-201357 - an experimental drug developed by the South San Francisco biotechnology company, Cytokinetics - is expected to increase muscle sensitivity to calcium and ... read more
The drug, Olesoxime, in Phase III of clinical testing was recently found to be ineffective in patients. Trophos SA, the company conducting the study in Europe, was ... read more
A team of 23 researchers in the Davee Department of Neurology and Clinical Neurosciences at Northwestern's Feinberg School of Medicine suggest that the protein, ... read more
Amyotrophic Lateral Sclerosis (ALS), more commonly referred to as Lou Gehrig's disease, is a neuromuscular disease that causes damage to the nerve cells ... read more
On Thursday, May 5th 2011 at 3:00 p.m. EST there will be an informational web seminar for people with ALS interested in learning about the clinical trial of ... read more
BOSTON — Tracking the inexorable advance of amyotrophic lateral sclerosis, the deadly neuromuscular ailment better known as Lou Gehrig’s disease or ... read more
Uncovering a rare clue to a baffling disease, scientists at the University of Pennsylvania have discovered a genetic stutter that may influence the risk of developing ... read more
Congress passed legislation late yesterday to provide an additional $3 million in funding for the ALS registry at the Centers for Disease Control and Prevention. The ... read more
WASHINGTON -- On Tuesday afternoon, when most senators were preparing to leave Washington for the holiday recess, Tom Coburn was declaring his intention to stick ... read more